在周围动脉疾病和糖尿病足中,β-3上腺体受体激活剂的治疗潜力
Cameron J F Evans1,2, Sarah J Glastras1,2,3, Owen Tang1,2
1Kolling Institute, University of Sydney, Sydney, NSW 2006, Australia.
Biomedicines
|December 23, 2023
概括
像Mirabegron这样的β-3上腺受体激动剂在治疗外围动脉疾病和糖尿病足方面表现有前途. 它们通过减少氧化应激和增强氧化氧化物生产来改善血液流动并促进愈合.
科学领域:
- 血管生物学 血管生物学
- 药理学 药理学是指药理学的学科.
- 再生医学是一种再生医学.
背景情况:
- 周围动脉疾病和糖尿病足代表了大量的医疗保健费用.
- 这两种情况都涉及氧化应激,炎症和缺氧.
- 米拉贝格伦是一种β-3上腺受体激动剂,已被批准用于过度活跃的膀.
研究的目的:
- 审查beta-3上腺受体激动剂在治疗外围动脉疾病和糖尿病足的潜在重新用途.
- 探索涉及的潜在分子机制.
主要方法:
- 关于β-3上腺受体激动剂,周围动脉疾病和糖尿病足的研究的文献综述.
- 分析氧化应激,氧化和内皮功能在这些条件下的作用.
主要成果:
- 贝塔-3上腺体受体激动剂刺激重新合内皮氧化合成酶,增加氧化的产生.
- 这种作用减少了活性氧物种,改善了内皮功能,并促进了血管生成.
- 在外围动脉疾病中对内皮细胞修复的潜力,以及在缺氧组织中增强的输液.
结论:
- β-3上腺受体激动剂为外周动脉疾病和糖尿病足提供了一个有前途的治疗策略.
- 重新使用这些药物可能会改善治疗结果,并减少医疗负担.
相关概念视频
Adrenergic Antagonists: ɑ and β-Receptor Blockers
453
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
453
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
825
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
825
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
822
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
822
Adrenergic Agonists: Therapeutic Uses
781
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
781
Adrenergic Receptors: β Subtype
1.7K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.7K
Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341


